The goal of this program is to train MD and PhD postdoctoral fellows in biomedical research as it applied to Blood Coagulation and Vascular Biology. We offer an multi-disciplinary program that consists of didactic instruction seminars, and supervised research. Important elements of the curriculum are supervised by faculty advisors, formal course work, interactions between the trainee and the entire faculty, and the interactions between the trainee and his peers. Dr. Bruce Furie is the Associate Program Director. Faculty of the training program, all members of the Department of Medicine at Beth Israel Deaconess Medical Center and Harvard Medical School, include faculty from the Divisions of Hematology-Oncology, Experimental Medicine, Molecular Medicine, Signal Transduction and Growth Regulation. MD trainees are selected from about 100 applicants each year. Only those applicants with an explicit commitment to career in academic medicine and basic research are selected. The training plan is an integral part of the Hematology training program for physicians planning careers in academic medicine. It consists of a minimum of two years of supervised bench research and didactic instruction after completion of the major part of clinical sub- specialty training (funded by the Beth Israel Deaconess Medical Center). We also receive about 200 applications per year from candidates with the PhD degree or physicians applying solely for research training. The design of the program has been revised to take into account several factors that have become particular evident in the past five years: (a) The need for physicians to acquire knowledge of advances in molecular biology, protein biochemistry and cell biology; (b) need for an extended training experience to allow fellows to develop sophistication in modern, complex biomedical research; (c) the need for PhD scientists to understand the biology and pathobiology of the vascular system. The training grant application, although technically a new application, represents a competitive renewal of T32 HL07437 from a new institution. T32 HL07437 has been active for 20 years at New England Medical Center. With the relocation of Drs. of Drs. Bruce Furie and Barbara C. Furie and other training faculty from New England Medical Center to Beth Israel Deaconess Medical Center, this program has been enriched by the consolidation of this faculty with other new faculty members focused on blood coagulation and vascular biology. During the past 110 years, this training grant has supported 22 trainees (15 MD or MD/PhD and 7 PhD) mentored by Drs. Furie. Of these, 13 physicians have completed training: 11 (85%) have academic appointments and are engaged in research at major medical schools. All of the PhDs that have finished training are engaged in research. This training program has proved highly successful, and i greatly enriched by its move to Harvard Medical School and the addition of exceptional and committed training faculty.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Institutional National Research Service Award (T32)
Project #
5T32HL007917-05
Application #
6627532
Study Section
Special Emphasis Panel (ZHL1-CSR-K (F1))
Program Officer
Mondoro, Traci
Project Start
1999-07-01
Project End
2004-08-31
Budget Start
2003-09-01
Budget End
2004-08-31
Support Year
5
Fiscal Year
2003
Total Cost
$440,663
Indirect Cost
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02215
Sharda, Anish; Furie, Bruce (2018) Regulatory role of thiol isomerases in thrombus formation. Expert Rev Hematol 11:437-448
Higgins, Sarah J; De Ceunynck, Karen; Kellum, John A et al. (2018) Tie2 protects the vasculature against thrombus formation in systemic inflammation. J Clin Invest 128:1471-1484
De Ceunynck, Karen; Peters, Christian G; Jain, Abhishek et al. (2018) PAR1 agonists stimulate APC-like endothelial cytoprotection and confer resistance to thromboinflammatory injury. Proc Natl Acad Sci U S A 115:E982-E991
Jain, A; Barrile, R; van der Meer, A D et al. (2018) Primary Human Lung Alveolus-on-a-chip Model of Intravascular Thrombosis for Assessment of Therapeutics. Clin Pharmacol Ther 103:332-340
Stopa, Jack D; Zwicker, Jeffrey I (2018) The intersection of protein disulfide isomerase and cancer associated thrombosis. Thromb Res 164 Suppl 1:S130-S135
Stopa, Jack D; Baker, Katherine M; Grover, Steven P et al. (2017) Kinetic-based trapping by intervening sequence variants of the active sites of protein-disulfide isomerase identifies platelet protein substrates. J Biol Chem 292:9063-9074
Flaumenhaft, Robert; De Ceunynck, Karen (2017) Targeting PAR1: Now What? Trends Pharmacol Sci 38:701-716
Bowley, Sheryl R; Fang, Chao; Merrill-Skoloff, Glenn et al. (2017) Protein disulfide isomerase secretion following vascular injury initiates a regulatory pathway for thrombus formation. Nat Commun 8:14151
Jain, Abhishek; Graveline, Amanda; Waterhouse, Anna et al. (2016) A shear gradient-activated microfluidic device for automated monitoring of whole blood haemostasis and platelet function. Nat Commun 7:10176
Flaumenhaft, Robert; Furie, Bruce (2016) Vascular thiol isomerases. Blood 128:893-901

Showing the most recent 10 out of 34 publications